AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23074313 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus dosing of beta-lactam antibiotics
Number of subjects: 60
Study 20817548 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pulse transcranial magnetic stimulation (TMS)
Number of subjects: 0
Study 20817548 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired pulse transcranial magnetic stimulation (TMS)
Number of subjects: 0
Study 20817548 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired pulse TMS (2 ms inter‐stimulus interval)
Number of subjects: 0
Study 20817548 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired pulse TMS (15 ms inter‐stimulus interval)
Number of subjects: 0
Study 18333937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin + ergometrine maleate 0.25 mg + oxytocin 20 iu
Number of subjects: 48
Study 18333937 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 20 iu alone
Number of subjects: 48
Study 18333937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin + ergometrine maleate
Number of subjects: 48
Study 16424119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperetin‐7‐glucoside juice
Number of subjects: 16
Study 14586584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions via electromyostimulation (EMS); 5 sets of 10 contractions (2 s on/6 s off, 1 min between sets) followed by 3 sets of 10 contractions (1 s on/1 s off, 30 s between sets).
Number of subjects: 0
Study 14586584 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 0
Study 11780441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone plus misoprostol
Number of subjects: 45
Study 11780441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 45
Study 9257790 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate (LASA) 720 mg in 4 ml saline solution
Number of subjects: 26
Study 9257790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8289617 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive weight training
Number of subjects: 64
Study 8289617 — intervention group
Group type: COMPARATOR
Intervention: Traditional weight training
Number of subjects: 64
Study 8289617 — intervention group
Group type: COMPARATOR
Intervention: Plyometric training
Number of subjects: 64
Study 8289617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 3527387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam for 4 weeks
Number of subjects: 6
Study 3527387 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 6
Study 3527387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 6
Study 30354558 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously daily)
Number of subjects: 31
Study 30354558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26863265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygen-saturation target group (85 to 89%)
Number of subjects: 2108
Study 26863265 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygen-saturation target group (91 to 95%)
Number of subjects: 2108
Study 26863265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygen-saturation target group (85 to 89%) with revised oximeters
Number of subjects: 2108
Study 26863265 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygen-saturation target group (91 to 95%) with revised oximeters
Number of subjects: 2108
Study 24769399 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic diet (at least 80% organic food)
Number of subjects: 13
Study 22445439 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based contraceptive assessment module with individually tailored health materials (n=78)
Number of subjects: 224
Study 22445439 — intervention group
Group type: COMPARATOR
Intervention: Computer-based contraceptive assessment module without tailored materials (n=76)
Number of subjects: 224
Study 20684443 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils mouthrinse
Number of subjects: 0
Study 20684443 — intervention group
Group type: COMPARATOR
Intervention: 0.05% cetylpyridinium chloride mouthrinse (CPC)
Number of subjects: 0
Study 20684443 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study 18215565 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthened yellow signal timing (increased by about 1s)
Number of subjects: 6
Study 18215565 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light camera enforcement (introduced several months after yellow timing changes)
Number of subjects: 6
Study 18215565 — intervention group
Group type: COMPARATOR
Intervention: Comparison intersections (no red light cameras, yellow timing constant)
Number of subjects: 6
Study 16513301 — intervention group
Group type: EXPERIMENTAL
Intervention: MF11RCE (80mg isoflavone) per day for 90 days
Number of subjects: 109
Study 16513301 — intervention group
Group type: COMPARATOR
Intervention: Placebo of equal design
Number of subjects: 109
Study 12800859 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (0.1 g carbohydrate, Na+ 6 mmol x l(‐1))
Number of subjects: 9
Study 12800859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Na+ 2 mmol x l(‐1))
Number of subjects: 9
Study 12800859 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (6.5% carbohydrate, 6.5 g carbohydrate, Na+ 21 mmol x l(‐1))
Number of subjects: 9
Study 12800859 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution
Number of subjects: 9
Study 10800603 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours bed rest after sheath removal
Number of subjects: 51
Study 10800603 — intervention group
Group type: COMPARATOR
Intervention: 6 hours bed rest after sheath removal
Number of subjects: 51
Study 8919651 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma prorenin concentration in patients with proliferative retinopathy
Number of subjects: 22
Study 8919651 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF-I concentration in patients with proliferative retinopathy
Number of subjects: 22
Study 8919651 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between plasma prorenin and serum IGF-I concentrations
Number of subjects: 22
Study 8919651 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I levels in relation to renal function
Number of subjects: 22
Study 1524162 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction system 'Trach Care'
Number of subjects: 60
Study 1524162 — intervention group
Group type: COMPARATOR
Intervention: Conventional disposable suction system
Number of subjects: 60
Study 6435484 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-nitroglycerin (transdermal therapeutic system)
Number of subjects: 12
Study 6435484 — intervention group
Group type: COMPARATOR
Intervention: 2% nitroglycerin ointment (0.5 inch applied at 8 hr intervals over 10 cm2 of skin)
Number of subjects: 12
Study 31619089 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament threads
Number of subjects: 0
Study 31619089 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 30652395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA) features for PCV
Number of subjects: 95
Study 29358716 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational resistance-training programme (12 weeks, 36 sessions)
Number of subjects: 47
Study 29358716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 29358716 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational resistance-training programme
Number of subjects: 47
Study 26284816 — intervention group
Group type: EXPERIMENTAL
Intervention: Playworks intervention
Number of subjects: 27
Study 26284816 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 24701539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied in a single sitting divided into four sessions.
Number of subjects: 30
Study 24701539 — intervention group
Group type: COMPARATOR
Intervention: Sham control group (similar treatment without activating the LASER unit).
Number of subjects: 30
Study 22374345 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop and Go (SAG) strategy
Number of subjects: 42
Study 22374345 — intervention group
Group type: COMPARATOR
Intervention: 3-days switch (3DS) strategy
Number of subjects: 42
Study 20164251 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM and Tdap
Number of subjects: 0
Study 20164251 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM and saline placebo
Number of subjects: 0
Study 20164251 — intervention group
Group type: COMPARATOR
Intervention: Tdap and saline placebo
Number of subjects: 0
Study 17011662 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 443
Study 17011662 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 443
Study 15902372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-dobutamine stress echocardiography (Dip-Dob)
Number of subjects: 127
Study 15902372 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole-atropine stress echocardiography (Dip-Atro)
Number of subjects: 127
Study 15902372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dip-Dob
Number of subjects: 127
Study 15902372 — intervention group
Group type: COMPARATOR
Intervention: Dip-Atro
Number of subjects: 127
Study 11863235 — intervention group
Group type: EXPERIMENTAL
Intervention: guided threat focus and reappraisal
Number of subjects: 46
Study 11863235 — intervention group
Group type: EXPERIMENTAL
Intervention: safety-behavior utilization
Number of subjects: 46
Study 11863235 — intervention group
Group type: COMPARATOR
Intervention: exposure only control
Number of subjects: 46
Study 10629930 — intervention group
Group type: COMPARATOR
Intervention: Amiridin (80 mg daily for 10 weeks)
Number of subjects: 49
Study 10629930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (20 intravenous infusions of 30 ml in 150 ml of physiologic solution during 4 weeks) followed by amiridin (80 mg daily for 10 weeks)
Number of subjects: 49
Study 10629930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin followed by amiridin
Number of subjects: 49
Study 7771821 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic continuous blood cardioplegia and hypothermic perfusion
Number of subjects: 872
Study 7771821 — intervention group
Group type: COMPARATOR
Intervention: Normothermic continuous blood cardioplegia and normothermic perfusion
Number of subjects: 872
Study 1980310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 5
Study 6101934 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoreceptor antagonists (propranolol, oxprenolol, practolol, metoprolol, tolamolol)
Number of subjects: 23
Study 6101934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30460781 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Number of subjects: 442
Study 30460781 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 442
Study 28976976 — intervention group
Group type: COMPARATOR
Intervention: 20-week prednisolone treatment
Number of subjects: 868
Study 28976976 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-week prednisolone treatment
Number of subjects: 868
Study 26921548 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-D
Number of subjects: 300
Study 26921548 — intervention group
Group type: COMPARATOR
Intervention: Tdap
Number of subjects: 300
Study 24450727 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital planimetry (DP)
Number of subjects: 0
Study 24450727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruler technique (RT)
Number of subjects: 0
Study 21829156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (<20% fat)
Number of subjects: 31
Study 21829156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (>45% fat)
Number of subjects: 31
Study 19744006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride (REQUIP®, ADARTREL®)
Number of subjects: 0
Study 19744006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole dihydrochloride (MIRAPEX®, SIFROL®)
Number of subjects: 0
Study 19744006 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 receptor subtype-selective agonists
Number of subjects: 0
Study 17514185 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0
Study 17514185 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15920715 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 290
Study 15920715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 12196433 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (40 mU/m2)
Number of subjects: 15
Study 12196433 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (40 mU/m2)
Number of subjects: 15
Study 9841585 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Thymic Formula for 3 to 6 months
Number of subjects: 38
Study 9841585 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 38
Study 7859517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 20802
Study 2673622 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (300 to 600 mg every 8 hours)
Number of subjects: 20
Study 2673622 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam (mean effective dosage 427 mg every 8 hours)
Number of subjects: 20
Study 2673622 — intervention group
Group type: EXPERIMENTAL
Intervention: Recainam
Number of subjects: 20
Study 5420207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (Serenid-D) in green tablets
Number of subjects: 48
Study 5420207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (Serenid-D) in yellow tablets
Number of subjects: 48
Study 5420207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (Serenid-D) in red tablets
Number of subjects: 48
Study 5420207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' assessment of phobias
Number of subjects: 48
Study 31652347 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 0
Study 31652347 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 0
Study 29978873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus and lemon verbena polyphenols
Number of subjects: 0
Study 28204639 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D RANO criteria
Number of subjects: 148
Study 28204639 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric methods
Number of subjects: 148
Study 28204639 — intervention group
Group type: COMPARATOR
Intervention: Volumetric methods (excluding subtraction of non-enhancing from enhancing volume)
Number of subjects: 148
Study 26248573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 110 mg b.i.d.
Number of subjects: 2782
Study 26248573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 150 mg b.i.d.
Number of subjects: 2782
Study 26248573 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2782
Study 23948058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fab antivenom
Number of subjects: 12
Study 23948058 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2 antivenom
Number of subjects: 12
Study 20839665 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 41
Study 20839665 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 41
Study 18302514 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 microg sodium selenite per day orally for 3 months)
Number of subjects: 36
Study 18302514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18302514 — intervention group
Group type: COMPARATOR
Intervention: Selenium vs. Placebo
Number of subjects: 36
Study 16680261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle enhancement program including health education, low caloric diet, and exercise for 26 weeks
Number of subjects: 55
Study 16680261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle enhancement program
Number of subjects: 55
Study 14571609 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) 1.0 ml/kg
Number of subjects: 40
Study 14571609 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study 14571609 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI)
Number of subjects: 40
Study 11230471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose L-asparaginase (HD ASP) arm; weekly intramuscular administration of HD ASP 25,000 IU/m² for a total of 20 weeks.
Number of subjects: 705
Study 11230471 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SD ASP arm).
Number of subjects: 705
Study 9692708 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐Mag (70 mmol/day K, 35 mmol/day citrate and 17.6 mmol/day Mg)
Number of subjects: 36
Study 9692708 — intervention group
Group type: EXPERIMENTAL
Intervention: Urocit‐K (70 mmol/day K and 23.4 mmol/day citrate)
Number of subjects: 36
Study 9692708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7908130 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dipyridamole with 1360 mg glutamic acid HCl (achlorhydric subjects)
Number of subjects: 11
Study 7908130 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dipyridamole without pretreatment (achlorhydric subjects)
Number of subjects: 11
Study 7908130 — intervention group
Group type: COMPARATOR
Intervention: 40 mg famotidine (control subjects)
Number of subjects: 11
Study 7908130 — intervention group
Group type: COMPARATOR
Intervention: 50 mg dipyridamole with 40 mg famotidine (control subjects)
Number of subjects: 11
Study 7908130 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dipyridamole (both groups)
Number of subjects: 11
Study 2844492 — intervention group
Group type: EXPERIMENTAL
Intervention: Active marijuana (1.8% delta 9‐THC)
Number of subjects: 10
Study 2844492 — intervention group
Group type: EXPERIMENTAL
Intervention: Task performance (serial acquisition task)
Number of subjects: 10
Study 2844492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of drug and task performance
Number of subjects: 10
Study 2844492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30273288 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (TG)
Number of subjects: 33
Study 30273288 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise Control (CG)
Number of subjects: 33
Study 30672252 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with hydro-acupuncture (1 mL Danshen injection per point, 7 days per injection for 2 weeks)
Number of subjects: 100
Study 30672252 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture (once a day, six treatments per week for 2 weeks)
Number of subjects: 100
Study 27427553 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) with T gel for 12 weeks, followed by cessation for 8 weeks
Number of subjects: 50
Study 27427553 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 20 weeks in addition to TRT
Number of subjects: 50
Study 27427553 — intervention group
Group type: COMPARATOR
Intervention: Control group (TRT alone)
Number of subjects: 50
Study 27427553 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 20 weeks
Number of subjects: 50
Study 26632125 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine‐bupivacaine plus 1 ug/kg DEX retrobulbar block
Number of subjects: 200
Study 26632125 — intervention group
Group type: COMPARATOR
Intervention: lidocaine‐bupivacaine retrobulbar block
Number of subjects: 200
Study 23137954 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic management and home visits
Number of subjects: 544
Study 23137954 — intervention group
Group type: COMPARATOR
Intervention: Clinic management only
Number of subjects: 544
Study 21570549 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of Copper T380A IUD
Number of subjects: 215
Study 21570549 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of Copper T380A IUD
Number of subjects: 215
Study 18638709 — intervention group
Group type: EXPERIMENTAL
Intervention: QuYuHuaTanTongLuo Decoction (QYHTTLD)
Number of subjects: 69
Study 18638709 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 69
Study 17051484 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 10
Study 17051484 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 10
Study 17051484 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 10
Study 17051484 — intervention group
Group type: COMPARATOR
Intervention: TNF-alpha antagonists
Number of subjects: 10
Study 15339579 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinggan Huoxue Recipe
Number of subjects: 0
Study 15339579 — intervention group
Group type: COMPARATOR
Intervention: Xiao Chaihu Decoction
Number of subjects: 0
Study 15339579 — intervention group
Group type: COMPARATOR
Intervention: General supportive treatment
Number of subjects: 0
Study 10966000 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-day infusion of fluorouracil (1000 mg/m2/day) plus vinorelbine (20 mg/m2/i.v. day 1 and 5), recycled every 3 weeks for a total of six courses.
Number of subjects: 48
Study 9297886 — intervention group
Group type: EXPERIMENTAL
Intervention: Open appendectomy (group I)
Number of subjects: 32
Study 9297886 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (group II)
Number of subjects: 32
Study 9297886 — intervention group
Group type: COMPARATOR
Intervention: Both groups (open and laparoscopic)
Number of subjects: 32
Study 29374658 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year HPV screening with partial genotyping and referral of HPV16/18-positive women to colposcopy (intervention Arm B)
Number of subjects: 121000